3151July, 2017, Vadodara, India

PRESS RELEASE

Alembic Pharmaceuticals receives USFDA Approval for Doxycycli ne Capsules USP,75 mg and 1 00 mg.

Alembic Pharmaceuticals Limited today announced that the company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Doxycycline Capsules USP, 75 mg and 100 mg.The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD} Monodox® Capsules,75 mg and 100 mg,of Aqua Pharmaceuticals.Doxycycline Capsules are indicated for the treatment and prevention of infections that are proven or strongly suspected to be caused by bacteria.

Doxycycline Capsules USP, 75 mg and 100 mg,have an estimated market size of US$ 30 million for twelve months ending December 2016 according to IMS.

Alembic now has a total of 62 ANDA approvals (54 final approvals and 8 tentative approvals) from USFDA.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited,a vertically integrated research and development pharmaceutical company,has been at the forefront of healthcare since 1907.Headquartered in India,Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world.Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA.Alembic is one of the leaders in branded generics in India.Alemb ic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at http://www.alembicpharmaceuticals.com/;(Reuters:ALEM.NS) (Bloomberg: ALPM) (NSE: APLLTD) (BSE: 533573)

For more information contact:

Ajay Kumar Desai

Phone:+91 22 -306 11681

Email:ajay.desai@alembic .co.i n

Mitanshu Shah

Phone: +91 265 - 3007630

Email:mitanshu .shah@alembic. co.i n

ALEMBIC PHARMACEUTICALS LIMITED

REG.OFFICE :ALE BIC ROAD, VADODARA • 390 003. • TEL :(0265) 2280550,2280880 • FAX :(0265) 2281229

website :www.alemb1cpharmaceuticals.com • E-mail:alembic@alembic.co.in • CIN :L24230GJ2010PLC061123

Alembic Pharmaceuticals Limited published this content on 31 July 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 31 July 2017 07:09:09 UTC.

Original documenthttp://www.alembicpharmaceuticals.com/wp-content/uploads/2016/Investors/Statutory-Details/Notices-Correspondences/2016-2017/Press%20Release%20USFDA%20Approval%20Doxycycline%20Capsules%20USP,%20July,%202017.pdf

Public permalinkhttp://www.publicnow.com/view/B97C5E1872B7DA01C5FF09A6AE242C08A183EDF4